ExcellGene SA
Benjamin Moritz is a Business Development Manager at ExcellGene SA since January 2022, focusing on identifying opportunities to advance client projects in clinical trials. Previous experience includes serving as Head of Cell Line Development at Ichnos Sciences, leading an international team and managing research activities, and as Principal Scientist at Glenmark Pharmaceuticals, where oversight of the Cell Line Development team was emphasized. Benjamin's career began with roles at Roche, where work as a Research Scientist and a Ph.D. student advanced proficiency in cell line development and optimization. Educational credentials include an Executive MBA from Quantic School of Business and Technology, a Ph.D. in Epigenetics from Ludwig-Maximilians-Universität München, and advanced degrees in Molecular Biology and Biology from Technical University of Munich and University of Konstanz, respectively.
ExcellGene SA
Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.